secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2022-09-02T23:59:59+00:00
Accession:  0001493152-22-024982
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic receives CMC questions from European regulator; expects Q4 2022 trial start
--------------------------------------------------------------------------------

- Received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority on August 30, 2022.
- Company is addressing the questions and currently expects to commence clinical trials in Q4 2022.
- Protagenic is also finalizing its US submission for the same trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222024982/0001493152-22-024982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222024982/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-024982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer